Advertisement

Prostate Cancer Hypofractionation

  • Jordan A. Holmes
  • Ronald Chen
Chapter

Abstract

Prostate cancer is the most common malignancy diagnosed in men in the USA, and in 2016 it is estimated that over 180,000 men will be diagnosed with prostate cancer. Treatment options for prostate cancer are based on risk stratification with Gleason score, clinical stage, and PSA. Of interest to the radiation oncologist, prostate cancer is hypothesized to have an alpha/beta ratio of <2 offering a potential therapeutic benefit for hypofractionation. In addition to biological reasons, the frequency of prostate cancer and the high health-care cost of treatment have led to significant interest in shortening radiation treatment time. Recently several large randomized trials of hypofractionation have been published providing high quality level I evidence for the safety and efficacy of modest hypofractionation. There has been a more recent interest in SBRT for prostate cancer with many single and multiinstitutional studies reporting safety and efficacy.

Keywords

Prostate cancer Hypofractionation Stereotactic body radiotherapy External beam radiation 

References

  1. 1.
    Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(2):361–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–32.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1061–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Lukka H. RTOG 0938 protocol information minimize: a randomized phase II trial of hypofractionated radiotherapy for favorable risk prostate cancer—RTOG CCOP Study. 2016. https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0938. Accessed 19 June 2017.
  7. 7.
    Lewis SL, Patel P, Song H, et al. Image guided Hypofractionated Postprostatectomy intensity modulated radiation therapy for prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;94(3):605–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006;64(2):518–26.CrossRefPubMedGoogle Scholar
  9. 9.
    Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015;16(3):274–83.CrossRefPubMedGoogle Scholar
  10. 10.
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer Version 2.2017. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 6 Nov 2016.
  11. 11.
    Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860–8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. Jan 2012;13(1):43–54.CrossRefPubMedGoogle Scholar
  13. 13.
    Wilkins A, Mossop H, Syndikus I, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. Dec 2015;16(16):1605–16.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Catton CN, Lukka H, Julian JA, et al. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. Paper presented at American Society of Clinical Oncology 2016; Chicago, IL.Google Scholar
  15. 15.
    Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17(4):464–74.CrossRefPubMedGoogle Scholar
  16. 16.
    King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109(2):217–21.CrossRefPubMedGoogle Scholar
  17. 17.
    King CR, Collins S, Fuller D, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys. 2013;87(5):939–45.CrossRefPubMedGoogle Scholar
  18. 18.
    Boike TP, Lotan Y, Cho LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011;29(15):2020–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Cozzarini C, Fiorino C, Di Muzio N, et al. Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a Phase I-II study. Radiother Oncol. 2008;88(1):26–33.CrossRefPubMedGoogle Scholar
  20. 20.
    Massaccesi M, Cilla S, Deodato F, et al. Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial. Anticancer Res. 2013;33(6):2785–9.PubMedGoogle Scholar
  21. 21.
    Katayama S, Striecker T, Kessel K, et al. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. Int J Radiat Oncol Biol Phys. 2014;90(4):926–33.CrossRefPubMedGoogle Scholar
  22. 22.
    Gladwish A, Loblaw A, Cheung P, et al. Accelerated hypofractioned postoperative radiotherapy for prostate cancer: a prospective phase I/II study. Clin Oncol (R Coll Radiol). 2015;27(3):145–52.CrossRefGoogle Scholar
  23. 23.
    Kruser TJ, Jarrard DF, Graf AK, et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer. Jun 15 2011;117(12):2629–36.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyIndiana UniversityIndianapolisUSA
  2. 2.Indiana University Simon Cancer CenterIndianapolisUSA
  3. 3.Department of Radiation OncologyUniversity of North Carolina HospitalsChapel HillUSA
  4. 4.University of North Carolina-Lineberger Comprehensive Cancer CenterChapel HillUSA
  5. 5.Sheps Center for Health Services ResearchUniversity of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations